Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02599961 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)
A Phase 2 study, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02599961 is a Phase 2 study that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 15 participants.
The verdict
NCT02599961, a Phase 2 study, was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the long-term safety of UX007 in Glut1 DS participants.
Interventions
- DRUG UX007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-09-10 |
| Est. Completion | 2019-10-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02599961
The ClinicalTrials.gov registry entry for NCT02599961 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UX007 is the first listed.
NCT02599961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02599961 about?
NCT02599961 is a clinical study titled "Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)". The primary objective of the study is to evaluate the long-term safety of UX007 in Glut1 DS participants.
What is the current status of trial NCT02599961?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2015-09-10. Estimated completion is 2019-10-22.
What interventions are being tested in trial NCT02599961?
The interventions under investigation include: UX007 (DRUG).
Who is sponsoring clinical trial NCT02599961?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.